MacroGenics (MGNX)
(Real Time Quote from BATS)
$3.48 USD
-0.35 (-9.14%)
Updated Aug 5, 2024 10:12 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 41 - 60 ( 362 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
FDA Adcom Votes to Delay Retifanlimab Approval Decision; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Second Collaboration Agreement With Zai Lab Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Investor Focus on MGC018 at ASCO; 1Q21 Financials Reported; Raising to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Retifanlimab Regulatory Progress; 2020 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Retifanlimab Development Milestone Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Retifanlimab Snags Priority Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
A Quiver Full of Antibody Arrows; Assuming Coverage at Buy and $36 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R